Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000724235 | SCV000227869 | uncertain significance | not provided | 2018-07-10 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000456148 | SCV000542282 | uncertain significance | Dilated cardiomyopathy 1G; Autosomal recessive limb-girdle muscular dystrophy type 2J | 2016-10-09 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000724235 | SCV000620327 | likely benign | not provided | 2019-12-16 | criteria provided, single submitter | clinical testing | This variant is associated with the following publications: (PMID: 23396983) |
Athena Diagnostics | RCV000724235 | SCV001879654 | uncertain significance | not provided | 2021-03-05 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002444706 | SCV002734742 | uncertain significance | Cardiovascular phenotype | 2020-01-15 | criteria provided, single submitter | clinical testing | The p.V7628I variant (also known as c.22882G>A), located in coding exon 93 of the TTN gene, results from a G to A substitution at nucleotide position 22882. The valine at codon 7628 is replaced by isoleucine, an amino acid with highly similar properties. This variant has been reported in a hypertrophic cardiomyopathy cohort in conjunction with variants in other cardiac-related genes (Lopes LR et al. J. Med. Genet., 2013 Apr;50:228-39). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |